Sinocelltech Group (SHSE:688520) Interest Expense : ¥-112 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sinocelltech Group's interest expense for the three months ended in Mar. 2024 was ¥ -31 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-112 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sinocelltech Group's Operating Income for the three months ended in Mar. 2024 was ¥ 233 Mil. Sinocelltech Group's Interest Expense for the three months ended in Mar. 2024 was ¥ -31 Mil. Sinocelltech Group's Interest Coverage for the quarter that ended in Mar. 2024 was 7.56. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinocelltech Group Interest Expense Historical Data

The historical data trend for Sinocelltech Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocelltech Group Interest Expense Chart

Sinocelltech Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-10.97

-18.00

-33.73

-84.47

-111.52

Sinocelltech Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-30.05	-20.63	-29.92	-30.93	-30.77

Sinocelltech Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-112 Mil.

Sinocelltech Group (SHSE:688520) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinocelltech Group's Interest Expense for the three months ended in Mar. 2024 was ¥-31 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥233 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ¥1,191 Mil.

Sinocelltech Group's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	232.799	/	-30.774
	=	7.56

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Sinocelltech Group Ltd interest coverage is 3.7, which is low.

Sinocelltech Group (SHSE:688520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176

Website

http://www.sinocelltech.com

Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.

Executives

Xie Liang Zhi

Director

Sinocelltech Group (SHSE:688520) Headlines

No Headlines